INTRODUCTION
============

Liver cancer is a leading cause of mortality in Korea as well as worldwide \[[@b1-kjim-2018-040]\]. Hepatocellular carcinoma (HCC), the predominant form of liver cancer \[[@b2-kjim-2018-040]\], usually develops in patients with chronic liver disease. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common etiologies of HCC worldwide. However, a nationwide cohort study has shown that non-B non-C (NBNC) HCC constitutes about one-fourth of the cases of HCC in Korea \[[@b3-kjim-2018-040]\]. Potential etiologies for NBNC HCC include heavy alcohol use, autoimmune liver disease, vascular liver disease, genetic liver disease, non-alcoholic fatty liver disease (NAFLD), or prior HBV exposure.

In a study from a tertiary hospital in Korea, which assessed 329 NBNC HCC cases without heavy alcohol intake diagnosed between 2001 and 2010, prior HBV infection still showed a greater etiological role than that of NAFLD \[[@b4-kjim-2018-040]\]. In another study from a tertiary hospital in Korea, which assessed 523 NBNC HCC cases diagnosed between 2007 and 2009, 47.4% of NBNC HCC cases (not including those with specific causes) were associated with prior HBV exposure, while 10.6% and 2.8% had chronic alcohol intake or metabolic syndrome alone, respectively, as a risk factor, and many (39.2%) had two or three risk factors as a potential etiology \[[@b5-kjim-2018-040]\]. In another study that reported the clinical characteristics of 480 NBNC HCC patients diagnosed between 2003 and 2012 in a tertiary hospital in Korea, NBNC-HCC was reported to be associated with older age at diagnosis, more frequent occurrence of metabolic syndrome, and less aggressive tumor characteristics \[[@b6-kjim-2018-040]\], and burnt-out NAFLD has been suggested as a major cause of cryptogenic HCC.

NAFLD is a chronic liver disease, characterized by the findings of fat infiltration of the liver without significant alcohol intake or secondary causes for hepatic steatosis \[[@b7-kjim-2018-040]\]. NAFLD can progress to end-stage liver disease, such as cirrhosis and HCC. The incidence of obesity-related metabolic syndrome is rapidly increasing in Korea, resulting in an increasing prevalence of NAFLD \[[@b7-kjim-2018-040]\]. In contrast, the prevalence of HBV has recently been decreasing, especially among the younger generation \[[@b8-kjim-2018-040]\]. Hence, the relative etiological role of prior HBV infection and NAFLD in the development of NBNC HCC is expected to change in Korea.

In this study, we investigated the clinical features of NBNC HCC patients with particular focus on the potential etiology, mode of detection and prevalence of cirrhosis, using a more recent cohort (NBNC HCC patients diagnosed between 2010 and 2013), to investigate the clinical features of NBNC HCC patients in Korea.

METHODS
=======

Study setting and participants
------------------------------

This study is a single-center, retrospective cohort study using the Samsung Medical Center HCC registry data. The HCC registry of Samsung Medical Center is a prospective registry that records baseline clinical characteristics, tumor variables, and the initial treatment modalities of every newly-diagnosed HCC patient aged 18 years or older who received care at the Samsung Medical Center. A diagnosis of HCC was established either histologically or clinically according to the regional HCC guideline \[[@b9-kjim-2018-040],[@b10-kjim-2018-040]\]. We screened a total of 3,347 patients registered in the Samsung Medical Center HCC registry between January 2010 and December 2013. Among them, we included a total of 447 consecutive NBNC HCC patients, excluding those who had positive results for hepatitis B surface antigen (HBsAg) and/or anti-HCV. The study was approved by the Ethics Committee of Samsung Medical Center and was conducted in accordance with the principles of the Declaration of Helsinki. Because this study was based on a retrospective analysis of existing administrative and clinical data, the requirement for informed patient consent was waived by the Institutional Review Board of Samsung Medical Center (IRB No. 2018-01-151).

Variables and data collection
-----------------------------

We used the following variables collected from the HCC registry: age at diagnosis, gender, body mass index (BMI), mode of detection, Child-Pugh Class, tumor characteristics (e.g., number of tumors, maximal tumor size, presence of vascular invasion and/or extrahepatic spread), serum alpha-fetoprotein (AFP), prothrombin-induced by vitamin K antagonist-II (PIVKA-II) levels and initial treatment modality. For this study, we additionally collected several variables, including the presence of autoimmune liver disease, vascular liver disease, genetic liver disease, history of heavy alcohol use, family history of HCC, smoking use, diabetes, hypertension, dyslipidemia, coronary arterial disease and hepatitis B core antibody results, liver imaging and endoscopy results by reviewing electronic medical records, as the HCC registry did not contain these variables. Overall survival was defined as the time from diagnosis to the last follow-up or to death, whichever came first. The referral date was September 30, 2017.

Definitions
-----------

In this study, we defined cirrhosis based on a combination of histology, imaging, endoscopy, and fibrosis-4 score (FIB-4). For those without histologic data, we defined cirrhosis by applying the following criteria in stepwise order: imaging based on nodular liver surface or caudate lobe hypertrophy, presence of ascites with/ without diuretic use, endoscopy showing varices, and FIB-4 score. The FIB-4 score was calculated as originally described, using age, serum aspartate aminotransferase, alanine aminotransferase, and platelet count \[[@b11-kjim-2018-040]\]. We used a cutoff point of 3.25, which had a sensitivity of 55%, a specificity of 97%, and a positive predictive value of 65% for cirrhosis \[[@b11-kjim-2018-040],[@b12-kjim-2018-040]\].

The mode of detection was prospectively collected from the HCC registry by trained abstractors. The variable had three categories including under surveillance, incidental and symptomatic. In order to identify potential causes, the presence of specific liver disease, alcohol consumption, hepatitis B core IgG antibody, and metabolic diseases (diabetes, obesity, hypertension, and dyslipidemia) were examined. Heavy alcohol intake was defined as \> 14 standard drinks/week in males and \> 7 standard drinks in females or people aged ≥ 65 years (14 g of alcohol per one standard drink) over a period of three years \[[@b13-kjim-2018-040]-[@b15-kjim-2018-040]\]. Those with identifiable chronic liver disease, such as autoimmune liver disease, vascular liver disease, and genetic liver disease were classified as NBNC-O (other identifiable causes). In the absence of other identifiable causes, patients were first categorized into NBNC-A (alcohol) if they had a history of heavy alcohol use. Patients without other identifiable causes or a history of heavy alcohol use were classified as NBNCNA-NO (non-alcohol, no-other identifiable causes). We reviewed the records of NBNC-NA-NO patients for prior HBV infection, defined by positivity for hepatitis B core immunoglobulin G antibody (HBcIgG), and looked for the presence of metabolic risk factors, such as obesity (BMI ≥ 25 kg/m^2^), diabetes, hypertension and/or dyslipidemia. Diabetes was defined according to the American Diabetes Association guideline as follows: hemoglobin A1c ≥ 6.5%, fasting plasma glucose ≥126 mg/dL, 2-hour plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test, or classic symptoms with random plasma glucose ≥ 200 mg/dL \[[@b16-kjim-2018-040]\]. Hypertension was defined as ≥ 130/85 mmHg or in the current use of anti-hypertensive medication. Dyslipidemia was defined as total cholesterol ≥ 200 mg/dL or current statin use.

Statistical analysis
--------------------

All statistical analyses were conducted using SPSS version 24 software package (IBM Co., Armonk, NY, USA). Data are shown as the median (range), median (interquartile range), or number (%) of patients. The chisquare test, Fisher's exact test, and Mann-Whitney test were used to compare data regarding the baseline characteristics and variables between subgroups. Survival analyses were performed using the Kaplan-Meier method with the differences in survival curves assessed using the log-rank test. Cox proportional hazards models were used to estimate the hazard ratios for the variables. For all analyses, two-sided tests of significance were used with a *p* value of less than 0.05 considered to be statistically significant.

RESULTS
=======

Baseline characteristics and overall survival
---------------------------------------------

The baseline characteristics of the study patients are summarized in [Table 1](#t1-kjim-2018-040){ref-type="table"}. The median age of patients was 67 years. In terms of age distribution, 77.0% of patients were aged above 60 years. A majority of the patients (85.2%) were males. Most had preserved liver function, indicated by Child-Pugh class A (87.0%, 389/447). The number of tumors was single in 64.4% of patients. Portal vein invasion was observed in 20.1% of patients (90/447). The most common initial treatment modality was transarterial chemoembolization, followed by surgical resection. Mortality was observed in 209 patients during the median follow-up of 32.2 months (range, 0.1 to 90.3). The 1-, 3-, and 5-year survival rates were 72.7%, 47.4%, and 16.3%, respectively. In unadjusted analysis, the mode of detection, presence of liver cirrhosis, Child-Pugh class, Eastern Cooperative Oncology Group (ECOG) performance, number of tumors, tumor size, portal vein thrombosis, AFP levels, and initial treatment modality were all associated with survival ([Table 2](#t2-kjim-2018-040){ref-type="table"}). In multivariable adjusted analysis, tumor size, portal vein thrombosis, and initial treatment modality were found to be independent factors for survival ([Table 2](#t2-kjim-2018-040){ref-type="table"}).

Potential etiology and patient profiles based on potential etiology
-------------------------------------------------------------------

The potential etiologies of NBNC-HCC are presented in [Fig. 1](#f1-kjim-2018-040){ref-type="fig"}. Ten patients had specific identifiable causes (NBNC-O); four patients had autoimmune hepatitis, two had Budd-Chiari syndrome, three had biliary cirrhosis, and one had Wilson's disease. Among 437 patients without other identifiable causes, 61.1% (267/437) had a history of heavy alcohol use (NBNC-A). Of the 170 patients without heavy alcohol use or other identifiable causes (NBNC-NA-NO), 115 patients (67.6%) had available HBcIgG test results with 83.5% of them (96/115) being positive for the antibody. Metabolic risk factors, specifically diabetes, obesity, hypertension, and dyslipidemia were detected in 49.4%, 42.9%, 61.2%, and 14.7% of the patients, respectively.

Patients characteristics were compared according to potential etiology (NBNC-A vs. NBNC-NA-NO) as shown in [Table 3](#t3-kjim-2018-040){ref-type="table"}. NBNC-NA-NO patients were characterized by an older age at diagnosis (about half were diagnosed at an age above 70 years), while the NBNC-A group was almost exclusively composed of male patients (99.3%). Compared with NBNC-A patients, the group of NBNC-NA-NO patients was older and majority female with a greater incidence of dyslipidemia, family history of HCC, lower prevalence of liver cirrhosis, higher prevalence of single tumor and more favorable Barcelona Clinic Liver Cancer (BCLC) stage at diagnosis. Additionally, a higher number of NBNC-NA-NO patients underwent tumor resection. The presence of obesity or diabetes, HBcIgG positivity, Child-Pugh class, tumor size, incidence of portal vein thrombosis, and tumor markers did not significantly differ between the two groups. The incidence of hypertension was higher (61.2% vs. 52.1%, *p* = 0.061) and the proportion of cases detected under surveillance was lower (18.8% vs. 27.7%, *p* = 0.090) in NBNCNA-NO patients than in NBNC-A patients, although this difference was statistically marginal. There was no significant difference in overall survival between NBNCNA-NO and NBNC-A patients (*p* = 0.162) ([Fig. 2](#f2-kjim-2018-040){ref-type="fig"}).

When NBNC-NA-NO patients were compared according to HBcIgG positivity, there was no significant difference found in their baseline characteristics according to HBcIgG positivity, except that patients without HBcIgG presented with symptom more frequently ([Supplementary Table 1](#SD1-kjim-2018-040){ref-type="supplementary-material"}). However, only 19 patients were HBcIgG negative.

Prevalence of cirrhosis and mode of detection
---------------------------------------------

[Fig. 3](#f3-kjim-2018-040){ref-type="fig"} is a schematic diagram of the prevalence of cirrhosis based on histopathologic findings, imaging studies, the presence of varices on endoscopy, and an FIB-4 score greater than 3.25 as a cutoff point, sequentially. Overall, no evidence of cirrhosis was found histologically, radiologically, endoscopically, or through FIB-4 score in up to one-third (33%, 148/447) of NBNC HCC patients. The prevalence of cirrhosis according to potential etiologies of HCC was the highest (90%) in NBNC-O, followed by NBNC-A (70.4%) and NBNC-NA-NO (60%). The group of patients with cirrhosis was more comprised of patients with heavy alcohol use and diabetes, and less comprised of patients with dyslipidemia, than the group of patients without cirrhosis. Those with cirrhosis were also more commonly diagnosed under surveillance. NBNC-HCC patients with an absence of cirrhosis were more likely to have a single large tumor, which was more frequently treated with resection ([Table 4](#t4-kjim-2018-040){ref-type="table"}).

In terms of the mode of detection, 25.5% of patients 114/447) were diagnosed under HCC surveillance. When compared according to the mode of detection, those who presented with symptoms showed the lowest BMI, the lowest incidence of diabetes, the poorest ECOG, the larger tumor burden with a higher prevalence of portal vein thrombosis, a higher level of tumor markers, and a lower incidence of liver cirrhosis. Those diagnosed under surveillance showed poorer liver function and the highest incidence of liver cirrhosis ([Table 5](#t5-kjim-2018-040){ref-type="table"}). Comparing the survival curves according to the mode of detection, survival was significantly lower among those who presented with symptoms than those who were diagnosed under surveillance or incidentally (*p* \< 0.001) ([Supplementary Fig. 1](#SD2-kjim-2018-040){ref-type="supplementary-material"}). When the mode of detection was assessed according to potential etiologies, the rate of diagnosis under regular surveillance was the lowest (18.8%) in patients with NBNC-NA-NO, 80.0% in patients with NBNC-O, and 27.7% in patients with NBNC-A ([Fig. 4](#f4-kjim-2018-040){ref-type="fig"}). Further classification of NBNC-A and NBNC-NA-NO patients according to the presence of cirrhosis revealed that those diagnosed under surveillance accounted for a minority (5.1% for NBNC-A, 2.9% for NBNC-NA-NO) of the patients ([Supplementary Fig. 2](#SD3-kjim-2018-040){ref-type="supplementary-material"}).

DISCUSSION
==========

In this study, we analyzed a total of 447 consecutive NBNC HCC patients (13.4%) among 3,347 HCC patients registered in our institution. The proportion of NBNC HCC patients was slightly lower than the proportion reported from other hospitals in Korea, which ranged from 16.1% to 20.2% \[[@b5-kjim-2018-040],[@b17-kjim-2018-040]\], and was also lower than that indicated by the nationwide cohort study in Korea, which reported an NBNC HCC prevalence of 27.4% \[[@b3-kjim-2018-040]\]. In our cohort, the most common potential etiology of NBNC HCC was heavy alcohol use (n = 267, 59.7%). Patients with other identifiable causes comprised only 10 patients (2.2%). One hundred and seventy patients showed no history of heavy alcoholism or any other identifiable chronic liver disease. The 5-year survival rate of the cohort was 16.3% with tumor size, portal vein thrombosis, and initial treatment modality serving as independent risk factors for survival.

In our cohort, 170 patients were classified as NBNCNA-NO HCC. Despite missing data for quite a few patients, a majority of the NBNC-NA-NO patients showed positive results for anti-HBc, and many of these carried concomitant metabolic risk factors. Among 115 NBNCNA-NO patients with available HBcIgG results, 75 patients (65.2%) showed both HBcIgG positivity and had metabolic risk factors, 21 patients (18.1%) showed HBcIgG positivity without metabolic risk factors, 16 patients (13.7%) had metabolic risk factors without showing HBcIgG positivity, and only three patients (2.5%) showed HBcIgG negativity without metabolic risk factors. Consistent with our findings, another study on potential etiology of NBNC HCC in Korea suggested that prior HBV exposure, defined as anti-HBc positivity, could be a potential etiology in NBNC HCC patients \[[@b5-kjim-2018-040]\]. Another Korean study reported that cryptogenic HCC (no HBV, no HCV, and no alcohol) was significantly associated with higher visceral fat, suggesting that these patients may have burnt-out NAFLD-related HCC \[[@b6-kjim-2018-040]\]. NAFLD-related HCC has been well described in Western patients \[[@b18-kjim-2018-040],[@b19-kjim-2018-040]\], and is usually defined as HCC in patients with a histologic evidence of NAFLD, or the presence of metabolic syndrome in the absence of HCV, HBV, or alcoholic liver disease \[[@b18-kjim-2018-040]\]. However, HBsAg-negative patients with prior HBV exposure showed HBV DNA integration \[[@b20-kjim-2018-040]\], which might induce tumor formation associated with occult HBV infection \[[@b21-kjim-2018-040]\]. Korea is an endemic area of HBV \[[@b8-kjim-2018-040],[@b22-kjim-2018-040]\], where occult HBV infection has been reported among patients with isolated anti-HBc \[[@b23-kjim-2018-040]\] and can be an important risk factor for the development of HCC in patients without HBsAg \[[@b24-kjim-2018-040]\]. There can also be a synergistic effect on the development of HCC among patients with prior HBV exposure and concomitant metabolic risk factors \[[@b24-kjim-2018-040]\]. In this study, evidence of steatosis was found either radiologically or histologically in 33 patients. However, it was difficult to classify patients in the NBNC-NA-NO HCC category into occult HBV infection-related or NAFLD-related groups, because quite a bit of patient data were missing for anti-HBc results, many had both anti-HBc and metabolic risk factors, and burnt-out NAFLD-related HCC can be present where liver fat is depleted. Although the precise etiological factors (e.g., non-alcoholic fatty liver or occult HBV infection) and their relative contribution to hepatocarcinogenesis is yet to be determined, our data indicate that NBNC-NA-NO HCC cases are characterized by a high incidence of prior HBV exposure and concomitant metabolic risk factors, resulting in a synergistic effect on hepatocarcinogenesis.

In this study, a substantial number of NBNC HCC patients (33%) notably showed no evidence of cirrhosis based on histological, radiological, endoscopic, and serologic results. Another cohort study from Korea also reported the absence of cirrhosis in 27.5% of NBNC HCC patients \[[@b5-kjim-2018-040]\], with a cirrhosis rate comparable to that of our study. Several studies have reported that fibrosis and cirrhosis are not always necessary for the development of HCC, especially for NAFLD-related HCC \[[@b17-kjim-2018-040],[@b18-kjim-2018-040],[@b25-kjim-2018-040],[@b26-kjim-2018-040]\]. Kim et al. \[[@b27-kjim-2018-040]\] compared histologic findings between HBV-related HCC and NBNC HCC using data of surgically resected HCC patients in Korea and reported that most HBV-related HCC patients had septal fibrosis (85.6%, 297/360 patients) but were non-cirrhotic, while more than half (52.7%, 49/103 patients) of non-cirrhotic NBNC HCC patients had no fibrosis. In our study, the proportion of non-cirrhotic HCC patients was the lowest among NBNC-O HCC (10%) and the highest among NBNC-NA-NO HCC (40%). Thus, it is evident that HCC can develop in non-cirrhotic liver, which comprises a significant proportion of NBNC-NA-NO HCC cases.

In our cohort, only 25% of NBNC HCC patients were diagnosed under surveillance. The proportion diagnosed under surveillance was the lowest in the NBNCNA-NO group (19%) where the proportion of cirrhosis was the lowest (40%), and was the highest in the NBNC-O group (80%) where the proportion of cirrhosis was the highest (90%). Among patients without cirrhosis, those diagnosed under surveillance comprised a minority (5.1% of non-cirrhotic NBNC-A patients, 2.9% of non-cirrhotic NBNC-NA-NO patients). Similarly, 93.9% of the 114 patients diagnosed under surveillance had cirrhosis, while the cirrhosis rate was 57.7% among those diagnosed incidentally and symptomatically. In this study, we observed that those diagnosed under surveillance had better survival than symptomatic patients. Futher studies are needed that can provide the best strategies for identifying the at-risk population among NBNC patients who may benefit from HCC surveillance.

In this study, we observed a few unique characteristics of NBNC-NA-NO patients. When compared with NBNC-A patients, the age at diagnosis was significantly older in NBNC-NA-NO patients. Moreover, 80.6% of NBNC-NA-NO patients were aged 60 years or older and more than half (48.2%) were aged 70 and above. A majority of tumors were single (73.5%) and nearly half (48.8%) were larger than 5 cm. Lee et al. \[[@b6-kjim-2018-040]\], also suggested that cryptogenic HCC is associated with an older age at diagnosis and a higher prevalence of single nodular presentation than HCC originating in other chronic liver diseases. Adam et al. \[[@b28-kjim-2018-040]\] reported that hepatocarcinogenesis in a non-cirrhotic liver was associated with a reduced number of clonal hepatocellular patches, analogous to aging-related changes, which may explain the older age at diagnosis in the absence of cirrhosis in many NBNC-NA-NO patients. Another study from Korea also reported that patients with cryptogenic HCC were much older than those with HCC associated with other etiologies \[[@b17-kjim-2018-040]\]. However, the outcome of NBNCNA-NO HCC was similar to NBNC-A HCC, despite several differences in baseline characteristics.

There are some limitations of this study. First, as this was a retrospective study, some key variables (e.g., anti-HBc) were missing in a substantial number of patients. Misclassification bias may also be present, as histologic, radiologic, and endoscopic data used to define cirrhosis were based on existing electronic medical records developed by many doctors. Another limitation is possible inter-observer and intra-observer variation in defining cirrhosis histologically and radiologically, as well as in defining varices endoscopically, which may result in the over- or under-estimation of cirrhosis incidence in our population. However, since the doctors who evaluated the histologic, radiologic and endoscopic findings were unaware of the aim of this study, this type of bias is non-differential. Second, although we consecutively enrolled patients so as to minimize selection bias, this study was confined to a single referral center, and thus selection bias cannot be ruled out. Third, as discussed, NAFLD-related HCC could not be accurately assessed in this study.

In summary, we systematically analyzed consecutive NBNC HCC patients in a single center. The potential etiological factors of NBNC HCC patients included NBNC-A and NBNC-O, however, many patients were classified as NBNC-NA-NO. NBNC-NA-NO patients were characterized by a high incidence of anti-HBc and a high incidence of concomitant metabolic risk factors. Notably, 40% of NBNC-NA-NO patients showed no evidence of cirrhosis based on histology, radiology, endoscopy, and FIB-4 scores, and only 18.8% were diagnosed under HCC surveillance. These findings imply that prior HBV infection and metabolic risk factors may be major contributing factors in the development of HCC in NBNC-NA-NO patients in Korea, even in the absence of cirrhosis.

KEY MESSAGE
===========

1\. Heavy alcohol use or any other specific cause was not found in 38.0% of non-B non-C hepatocellular carcinoma (NBNC HCC) patients.

2\. These NBNC-NA-NO (non-alcohol no-other identifiable cause) HCC group showed the highest proportion of non-cirrhotic patients (40.0%) and the lowest proportion of diagnosis under regular surveillance (18.8%).

3\. Prior hepatitis B virus infection and metabolic risk factors may be major causes of HCC in NBNC-NA-NO patients.
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###### 

Comparison of patients with NBNC-NA-NO according to HBcIgG positivity

###### 

Mode of detection and survival.

###### 

Mode of detection based on potential etiology and presence of cirrhosis. NBNC-A, non-B non-C alcohol; NBNC-NA-NO, non-alcohol, no-other identifiable cause.

![Potential etiology of non-B non-C (NBNC) hepatocellular carcinoma. NBNC-O, other identifiable cause; NBNC-A, alcohol; NBNC-NA-NO, non-alcohol, no-other identifiable cause; HBcIgG, hepatitis B core immunoglobulin G antibody.](kjim-2018-040f1){#f1-kjim-2018-040}

![Kaplan-Meier curves for overall survival between non-B non-C (NBNC)-A and NBNC-NA-NO. NBNC-A, alcohol; NBNC-NA-NO, non-alcohol, no-other identifiable cause.](kjim-2018-040f2){#f2-kjim-2018-040}

![Prevalence of cirrhosis based on multiple criteria. EGD, esophagogastroduodenoscopy; FIB-4, fibrosis-4 score.](kjim-2018-040f3){#f3-kjim-2018-040}

![Mode of detection based on potential etiology. NBNC-O, non-B non-C other identifiable cause; NBNC-A, alcohol; NBNC-NA-NO, non-alcohol, no-other identifiable cause.](kjim-2018-040f4){#f4-kjim-2018-040}

###### 

Overall characteristics of study population (n = 447)

  Variable                                                                  Value
  ------------------------------------------------------------------------- ---------------------
  Age, yr                                                                   67 (26--88)
   \< 50                                                                    29 (6.5)
   50--59                                                                   74 (16.6)
   60--69                                                                   167 (37.4)
   ≥ 70                                                                     177 (39.6)
  Male sex                                                                  381 (85.2)
  Body mass index^[a](#tfn1-kjim-2018-040){ref-type="table-fn"}^, kg/m^2^   24.5 (15.9--37.6)
   \< 18.5                                                                  10 (2.2)
   18.5--22.9                                                               143 (32.0)
   23.0--24.9                                                               95 (21.3)
   ≥ 25                                                                     191 (42.7)
  Family history of HCC                                                     29 (6.5)
  Heavy alcohol use                                                         269 (60.2)
  Smoking                                                                   
   Never                                                                    200 (44.7)
   Ex-smoker                                                                133 (29.8)
   Current smoker                                                           114 (25.5)
  Diabetes                                                                  211 (47.2)
  Hypertension                                                              246 (55.0)
  Dyslipidemia                                                              46 (10.3)
  Coronary arterial disease                                                 25 (5.8)
  Mode of detection                                                         
   Under surveillance                                                       114 (25.5)
   Incidental                                                               196 (43.8)
   Symptomatic                                                              137 (30.6)
  HBcIgG^[b](#tfn2-kjim-2018-040){ref-type="table-fn"}^                     
   Yes                                                                      235 (52.6)
   No                                                                       58 (13.0)
  Child-Pugh class                                                          
   A                                                                        389 (87.0)
   B                                                                        53 (11.9)
   C                                                                        5 (1.1)
  Albumin, g/dL                                                             4.2 (2.4--5.3)
  Bilirubin, g/dL                                                           0.8 (0.2--37.8)
  AST, U/L                                                                  39 (13--659)
  ALT, U/L                                                                  27 (7--368)
  PT, INR                                                                   1.05 (0.85--6.19)
  Platelet, × 10^3^/μL                                                      161 (17--544)
  No. of tumors                                                             
   1                                                                        288 (64.4)
   2--3                                                                     98 (22.0)
   ≥ 4                                                                      41 (9.1)
   Diffuse or infiltrative                                                  20 (4.5)
  Maximal tumor diameter, cm                                                
   \< 5                                                                     250 (55.9)
   ≥ 5                                                                      197 (44.1)
  Portal vein invasion                                                      90 (20.1)
  AFP^[c](#tfn3-kjim-2018-040){ref-type="table-fn"}^                        11.1 (0.9--600,000)
   \< 10                                                                    207 (46.3)
   10--100                                                                  105 (23.5)
   ≥ 100                                                                    134 (30.0)
  PIVKA-II                                                                  120 (6--75,000)
  Initial treatment modality                                                
   Resection                                                                117 (26.2)
   RF ablation                                                              72 (16.1)
   TACE                                                                     177 (39.6)
   Others                                                                   39 (8.7)
   Best supportive care                                                     42 (9.4)

Values are presented as median (range) or number (%).

HCC, hepatocellular carcinoma; HBcIgG, hepatitis B core immunoglobulin G antibody; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein; PIVKA-II, prothrombin-induced by vitamin K antagonist-II; RF, radiofrequency; TACE, transarterial chemoembolization.

Missing in eight patients.

Missing in 154 patients.

Missing in one patient.

###### 

Risk factors for overall survival

  Variable                     Unadjusted             Multivariable                          
  ---------------------------- ---------------------- --------------- ---------------------- ----------
  Age                          1.00 (0.99--1.01)      0.989           1.00 (0.99--1.02)      0.680
  Male sex                     0.83 (0.57--1.19)      0.305                                  
  Body mass index              1.00 (0.96--1.04)      0.810                                  
  Heavy alcohol use            1.21 (0.91--1.61)      0.194           1.20 (0.89--1.63)      0.237
  Diabetes                     0.86 (0.66--1.13)      0.284                                  
  Hypertension                 0.87 (0.66--1.14)      0.297                                  
  Dyslipidemia                 1.06 (0.67--1.66)      0.816                                  
  Family history of HCC        0.92 (0.52--1.61)      0.768                                  
  Smoking                                                                                    
   Never                       1                                                             
   Ex-smoker                   0.98 (0.71--1.33)      0.872                                  
   Current smoker              0.81 (0.57--1.15)      0.231                                  
  Mode of detection                                                                          
   Under surveillance          1                                      1                      
   Incidental                  0.82(0.57--1.18)       0.286           0.81 (0.55--1.19)      0.282
   Symptomatic                 2.12 (1.50--2.99)      \< 0.001        1.24 (0.82--1.87)      0.315
  HBcIgG                                                                                     
   No                          1                                      1                      
   Yes                         0.80 (0.54--1.18)      0.263           0.76 (0.50--1.15)      0.191
   Missing                     0.68 (0.45--1.03)      0.068           0.78 (0.50--1.21)      0.273
  Liver cirrhosis              1.56 (1.14--2.13)      0.005           1.25 (0.88--1.77)      0.211
  Child-Pugh class                                                                           
   A                           1                                      1                      
   B                           2.11 (1.47--3.02)      \< 0.001        1.28 (0.83--1.98)      0.264
   C                           5.74 (2.34--14.09)     \< 0.001        1.90 (0.69--5.22)      0.215
  ECOG                                                                                       
   0                           1                                      1                      
   ≥ 1                         1.50 (1.01--2.24)      0.045           1.01 (0.65--1.58)      0.961
  No. of tumors                                                                              
   Single                      1                                      1                      
   Multiple                    1.79 (1.34--2.38)      \< 0.001        1.14 (0.83--1.56)      0.430
   Diffuse/infiltrative        8.14 (4.96--13.38)     \< 0.001        1.58 (0.88--2.86)      0.126
  Tumor size, cm                                                                             
   \< 5                        1                                      1                      
   ≥ 5                         2.70 (2.05--3.56)      \< 0.001        1.76 (1.19--2.60)      0.005
  Portal vein thrombosis       4.23 (3.16--5.66)      \< 0.001        2.10 (1.44--3.06)      \< 0.001
  Log~10~ AFP                  1.40 (1.28--1.54)      \< 0.001        1.06 (0.94--1.20)      0.333
  Initial treatment modality                                                                 
   Resection                   1                                      1                      
   RF ablation                 1.73 (0.90--3.33)      0.100           2.25 (1.12--4.54)      0.023
   TACE                        5.59 (3.39--9.25)      \< 0.001        4.09 (2.40--6.98)      \< 0.001
   Others                      10.19 (5.61--18.51)    \< 0.001        6.02 (3.22--11.26)     \< 0.001
   Best supportive care        43.25 (23.99--77.98)   \< 0.001        24.09 (12.29--47.22)   \< 0.001

HR, hazard ratio; CI, confidence interval; HCC, hepatocellular carcinoma; HBcIgG, hepatitis B core immunoglobulin G antibody; ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein; RF, radiofrequency; TACE, transarterial chemoembolization.

###### 

Comparison of NBNC-A versus NBNC-NA-NO (n = 437)

  Variable                                                                  NBNC-A (n = 267)        NBNC-NA-NO (n = 170)    *p* value
  ------------------------------------------------------------------------- ----------------------- ----------------------- -----------
  Age, yr                                                                                                                   0.011
   \< 50                                                                    16 (6.0)                11 (6.4)                
   50--59                                                                   52 (19.5)               22 (12.9)               
   60--69                                                                   110 (41.2)              55 (32.4)               
   ≥ 70                                                                     89 (33.3)               82 (48.2)               
  Male sex                                                                  265 (99.3)              112 (65.9)              \< 0.001
  Body mass index^[a](#tfn4-kjim-2018-040){ref-type="table-fn"}^, kg/m^2^                                                   0.994
   \< 18.5                                                                  6 (2.2)                 4 (2.4)                 
   18.5--22.9                                                               85 (31.8)               56 (32.9)               
   23.0--24.9                                                               58 (21.7)               34 (20.0)               
   ≥ 25                                                                     113 (42.3)              73 (42.9)               
  Diabetes                                                                  122 (45.7)              84 (49.4)               0.448
  Hypertension                                                              139 (52.1)              104 (61.2)              0.061
  Dyslipidemia                                                              20 (7.5)                25 (14.7)               0.023
  Family history of HCC                                                     9 (3.4)                 20 (11.8)               0.001
  Mode of detection                                                                                                         0.090
   Under surveillance                                                       74 (27.7)               32 (18.8)               
   Incidental                                                               111 (41.6)              84 (49.4)               
   Symptomatic                                                              82 (30.7)               54 (31.8)               
  HBcIgG^[b](#tfn5-kjim-2018-040){ref-type="table-fn"}^                                                                     0.399
   Yes                                                                      134 (50.2)              96 (56.5)               
   No                                                                       38 (14.2)               19 (11.2)               
  Liver cirrhosis                                                           188 (70.4)              102 (60.0)              0.029
  Child-Pugh class                                                                                                          0.657
   A                                                                        229 (85.8)              151 (88.8)              
   B                                                                        35 (13.1)               17 (10.0)               
   C                                                                        3 (1.1)                 2 (1.2)                 
  No. of tumors                                                                                                             0.003
   Single                                                                   155 (58.1)              125 (73.5)              
   Multiple                                                                 99 (37.1)               38 (22.4)               
   Diffuse/infiltrative                                                     13 (4.9)                7 (4.1)                 
  Tumor size, cm                                                                                                            0.168
   \< 5                                                                     155 (58.1)              87 (51.2)               
   ≥ 5                                                                      112 (41.9)              83 (48.8)               
  Portal vein thrombosis                                                    54 (20.2)               34 (20.0)               0.954
  BCLC stage                                                                                                                0.042
   0                                                                        24 (9.0)                18 (10.6)               
   A                                                                        105 (39.3)              84 (49.4)               
   B                                                                        44 (16.5)               13 (7.6)                
   C                                                                        90 (33.7)               51 (30.0)               
   D                                                                        4 (1.5)                 4 (2.4)                 
  AFP                                                                       11.1 (5.5--146.9)       11.3 (4.8--666.3)       0.807
  PIVKA-II                                                                  132.0 (34.5--1,200.0)   119.0 (25.0--1,200.0)   0.341
  Initial treatment modality                                                                                                0.013
   Resection                                                                59 (21.9)               58 (32.6)               
   RF ablation                                                              40 (14.9)               32 (18.0)               
   TACE                                                                     121 (45.0)              56 (31.5)               
   Others                                                                   27 (10.0)               12 (6.7)                
   Best supportive care                                                     22 (8.2)                20 (11.2)               

Values are presented as number (%) or median (interquartile range).

NBNC-A, non-B non-C alcohol; NBNC-NA-NO, non-alcohol, no-other identifiable cause; HCC, hepatocellular carcinoma; HBcIgG, hepatitis B core immunoglobulin G antibody; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; PIVKA-II, prothrombin-induced by vitamin K antagonist-II; RF, radiofrequency; TACE, transarterial chemoembolization.

Missing in five and three patients, respectively.

Missing in 95 (35.6%) and 55 (32.4%) patients, respectively.

###### 

Comparison of characteristics according to the presence of cirrhosis in NBNC-HCC (n = 447)

  Variable                                                                  Non-cirrhosis (n = 148)   Cirrhosis (n = 299)    *p* value
  ------------------------------------------------------------------------- ------------------------- ---------------------- -----------
  Age, yr                                                                   66 (58--73)               67 (61--73)            0.446
  Male sex                                                                  129 (87.2)                252 (84.3)             0.419
  Body mass index^[a](#tfn6-kjim-2018-040){ref-type="table-fn"}^, kg/m^2^                                                    0.680
   \< 18.5                                                                  4 (2.7)                   6 (2.0)                
   18.5--22.9                                                               51 (34.5)                 92 (30.8)              
   23.0--24.9                                                               30 (20.3)                 65 (21.7)              
   ≥ 25                                                                     62 (41.9)                 129 (43.1)             
  Heavy alcohol use                                                         79 (53.4)                 190 (63.5)             0.039
  Diabetes                                                                  54 (36.2)                 158 (51.6)             0.001
  Hypertension                                                              84 (56.8)                 162 (54.2)             0.606
  Dyslipidemia                                                              23 (15.5)                 23 (7.7)               0.010
  Family history of HCC                                                     14 (9.5)                  15 (5.0)               0.073
  Mode of detection                                                                                                          \< 0.001
   Under surveillance                                                       7 (4.7)                   107 (35.8)             
   Incidental by screening                                                  83 (56.1)                 113 (37.8)             
   Symptomatic                                                              58 (39.2)                 79 (26.4)              
  HBcIgG^[b](#tfn7-kjim-2018-040){ref-type="table-fn"}^                                                                      0.802
   Yes                                                                      76 (51.4)                 159 (53.2)             
   No                                                                       18 (12.2)                 40 (13.4)              
  Child-Pugh class                                                                                                           \< 0.001
   A                                                                        146 (98.6)                243 (81.3)             
   B                                                                        2 (1.4)                   51 (17.1)              
   C                                                                        0                         5 (1.7)                
  No. of tumors                                                                                                              0.004
   Single                                                                   111 (75.0)                177 (59.2)             
   Multiple                                                                 32 (21.6)                 107 (35.8)             
   Diffuse/infiltrative                                                     5 (3.4)                   15 (5.0)               
  Tumor size, cm                                                                                                             \< 0.001
   \< 5                                                                     60 (40.5)                 190 (63.5)             
   ≥ 5                                                                      88 (59.5)                 109 (36.5)             
  Portal vein thrombosis                                                    24 (16.2)                 66 (22.1)              0.146
  BCLC stage                                                                                                                 0.010
   0                                                                        8 (5.4)                   39 (13.0)              
   A                                                                        73 (49.3)                 119 (39.8)             
   B                                                                        16 (10.8)                 41 (13.7)              
   C                                                                        51 (34.5)                 92 (30.8)              
   D                                                                        0                         8 (2.7)                
  AFP                                                                       10.7 (3.7--348.5)         11.3 (6.0--226.5)      0.225
  PIVKA-II                                                                  185.0 (33.0--1,200.0)     94.0 (27.0--1,200.0)   0.152
  Initial treatment                                                                                                          \< 0.001
  Resection                                                                 64 (43.2)                 53 (17.7)              
  RF ablation                                                               17 (11.5)                 55 (18.4)              
  TACE                                                                      43 (29.1)                 134 (44.8)             
  Others                                                                    16 (10.8)                 23 (7.7)               
  Best supportive care                                                      8 (5.4)                   34 (11.4)              

Values are presented as median (interquartile range) or number (%).

NBNC, non-B non-C; HCC, hepatocellular carcinoma; HBcIgG, hepatitis B core immunoglobulin G antibody; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; PIVKA-II, prothrombin-induced by vitamin K antagonist-II; RF, radiofrequency; TACE, transarterial chemoembolization.

Missing in one and seven patients, respectively.

Missing in 54 (36.5%) and 100 (33.4%) patients, respectively.

###### 

Comparison based on mode of detection

  Variable                                                Under surveillance (n = 114)   Incidental (n = 196)   Symptomatic (n = 137)      *p* value
  ------------------------------------------------------- ------------------------------ ---------------------- -------------------------- -----------
  Age, yr, median (IQR)                                   66 (60--72)                    68 (61--73)            66 (56--73)                0.296
  Male sex                                                90 (78.9)                      171 (87.2)             120 (87.6)                 0.090
  Body mass index                                         24.8 (22.9--27.1)              24.5 (22.0--26.8)      23.5 (21.4--25.7)          0.006
  Heavy alcohol use                                       75 (65.8)                      111 (56.6)             83 (60.6)                  0.281
  Diabetes                                                65 (57.0)                      93 (47.4)              53 (38.7)                  0.015
  Hypertension                                            58 (50.9)                      115 (58.7)             73 (53.3)                  0.365
  Dyslipidemia                                            7 (6.1)                        21 (10.7)              18 (13.1)                  0.186
  Family history of HCC                                   8 (7.0)                        11 (5.6)               10 (7.3)                   0.799
  HBcIgG^[b](#tfn8-kjim-2018-040){ref-type="table-fn"}^                                                                                    0.294
   Yes                                                    55 (48.2)                      111 (56.6)             69 (50.4)                  
   No                                                     12 (10.5)                      24 (12.2)              22 (16.1)                  
  Liver cirrhosis                                         107 (93.9)                     113 (57.7)             79 (57.7)                  \< 0.001
  Child-Pugh class                                                                                                                         0.017
   A                                                      90 (78.9)                      178 (90.8)             121 (88.3)                 
   B                                                      23 (20.2)                      15 (7.7)               15 (10.9)                  
   C                                                      1 (0.9)                        3 (1.5)                1 (0.7)                    
  ECOG                                                                                                                                     0.040
   0                                                      105 (92.1)                     180 (91.8)             115 (83.9)                 
   ≥ 1                                                    9 (7.9)                        16 (8.2)               22 (16.1)                  
  No. of tumors                                                                                                                            0.334
   Single                                                 70 (61.4)                      129 (65.8)             89 (65.0)                  
   Multiple                                               40 (35.1)                      61 (31.1)              38 (27.7)                  
   Diffuse/infiltrative                                   4 (3.5)                        6 (3.1)                10 (7.3)                   
  Tumor size, cm                                                                                                                           \< 0.001
   \< 5                                                   99 (86.8)                      114 (58.2)             37 (27.0)                  
   ≥ 5                                                    15 (13.2)                      82 (41.8)              100 (73.0)                 
  Portal vein thrombosis                                  11 (9.6)                       31 (15.8)              48 (35.0)                  \< 0.001
  BCLC stage                                                                                                                               \< 0.001
   0                                                      25 (21.9)                      19 (9.7)               3 (2.2)                    
   A                                                      52 (45.6)                      93 (47.4)              47 (34.3)                  
   B                                                      15 (13.2)                      31 (15.8)              11 (8.0)                   
   C                                                      21 (18.4)                      50 (25.5)              72 (52.6)                  
   D                                                      1 (0.9)                        3 (1.5)                4 (2.9)                    
  AFP                                                     7.5 (4.6--18.5)                10.9 (4.8--200.1)      52.9 (8.3--7464.3)         \< 0.001
  PIVKA-II, median (IQR)                                  43.0 (21.0--142.0)             95.0 (30.0--1,013.0)   1,200.0 (114.0--1,200.0)   \< 0.001
  Initial treatment modality                                                                                                               \< 0.001
   Resection                                              15 (13.2)                      73 (37.2)              29 (21.2)                  
   RF ablation                                            36 (31.6)                      28 (14.3)              8 (5.8)                    
   TACE                                                   51 (44.7)                      71 (36.2)              55 (40.1)                  
   Others                                                 5 (4.4)                        13 (6.6)               21 (15.3)                  
   Best supportive care                                   7 (6.1)                        11 (5.6)               24 (17.5)                  

Values are presented as number (%) or median (range) unless otherwise indicated.

IQR, interquartile range; HCC, hepatocellular carcinoma; HBcIgG, hepatitis B core immunoglobulin G antibody; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; PIVKA-II, prothrombin-induced by vitamin K antagonist-II; RF, radiofrequency; TACE, transarterial chemoembolization.

Missing in 47 (41.2%), 61 (31.1%) and 46 (33.6%) patients, respectively.
